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Background: Frailty is an essential consideration with potentially inappropriate medications (PIMs), 62 
especially among older women.  63 
Aims: This study determined the use of potentially inappropriate medications according to frailty status 64 
using the Beers Criteria 2019, identified medications that should be flagged as potentially inappropriate 65 
and harmful depending on individual health factors, and determined the association between frailty and 66 
PIMs, adjusted for characteristics associated with PIMs. 67 
Methods: This prospective longitudinal study included 9355 participants aged 77 to 82 years at 68 
baseline (2003). Frailty was measured using the FRAIL (Fatigue, Resistance, Ambulation, Illness, & 69 
Loss of Weight) scale. Generalised estimating equations using log-binomial regressions determined the 70 
association between frailty and risk of using PIMs.  71 
Results: Among participants who were frail and non-frail at baseline, the majority used ≥3 PIMs (74.2% 72 
and 58.5%, respectively). At 2017, the proportion using ≥3 PIMs remained constant in the frail group 73 
(72.0%) but increased in the non-frail group (66.0%). Commonly prescribed medications that may be 74 
potentially inappropriate in both groups included benzodiazepines, proton-pump inhibitors and 75 
nonsteroidal anti-inflammatory drugs, and risperidone was an additional contributor in the non-frail 76 
group. When adjusted for other characteristics, frail women had a 2% higher risk of using PIMs (RR 77 
1.02; 95% CI: 1.01, 1.03).  78 
Conclusion: Given that the majority of frail women were using medications that may have been 79 
potentially inappropriate, it is important to consider both frailty and PIMs as indicators of health 80 
outcomes, and to review the need for PIMs for women aged 77 to 96 years who are frail. 81 
 82 








Introduction  91 
 92 
Given the increased risk for adverse events such as delirium, falls, fractures, hallucination, confusion 93 
and mortality [1, 2], interdisciplinary expert panels regularly review, and update medications/medication 94 
classes deemed as potentially inappropriate medications (PIMs) for older adults [3]. The Beers Criteria 95 
are the longest standing list of PIMs and have been widely used in the last two decades to examine 96 
prescribing patterns within populations and cost and utilisation data, to evaluate health outcomes, and 97 
to educate clinicians [4]. First developed in 1991 by Dr Mark Beers, the Beers Criteria have undergone 98 
multiple revisions and updates; the American Geriatrics Society assumed the responsibility of three-99 
yearly updates from 2012, with the latest version released in 2019 [3].  100 
 101 
The Beers Criteria lists PIMs that should generally be avoided among older adults as the potential risks 102 
of adverse effects outweigh their benefits. The list also recommends the avoidance of some 103 
medications/medication classes on the basis of long duration, high doses, creatinine clearance, and 104 
certain diseases; it also includes PIMs that should be used with caution in all older people [3]. Although 105 
most health researchers and clinicians are able to identify the appropriateness of PIMs based on these 106 
pre-specified criteria, longitudinal studies may not have the same access to patient health data. 107 
However, longitudinal studies are increasingly popular [5] as they allow for repeated measures of the 108 
same individuals over time [6]. Therefore, longitudinal studies can flag medications that may be 109 
potentially inappropriate, and attention should be paid during the medication review process so as to 110 
determine their appropriateness among older people. 111 
 112 
Frailty is an essential concept to consider in relation to PIM use. A geriatric syndrome triggered by 113 
multiple determinants, frailty is often characterised by reduced muscle endurance, strength and 114 
physiological function leading to higher dependency [7]. Frail older adults are more vulnerable to 115 
adverse events due to deficits in multiple physiological systems, and medication optimisation is crucial 116 
in this population. Optimisation may be challenging given the complexities associated with the presence 117 
of multiple morbidities, polypharmacy, and the potential for medication interactions, as well as a diverse 118 
and sometimes unpredictable response to medications [8].  119 
 120 
Older women are at higher risk of using PIMs compared to older men [5]. Women represent a greater 121 
proportion of older adults due to longer life expectancy [6], and older women are more likely to have 122 
multiple morbidities, use more medications, obtain health care services and receive diagnoses [7]. 123 
However, there is a lack of evidence about the prevalence of PIMs according to frailty status, especially 124 
among older women in later life [9-11]. Although prevalence of PIMs among frail and non-frail women 125 
may provide insight into the association with frailty, most studies have not discerned the differences 126 
between the two populations [8, 9]. Therefore, despite the possible relationship between frailty and 127 
PIMs, there is a gap in the literature regarding their association, and a lack of information about other 128 
characteristics associated with PIM use among frail older adults. Two recent European studies 129 
determined the incidence of frailty and changes in frailty status but to the best of our knowledge, ours 130 
is the first to determine the prevalence of PIMs in the context of frailty in the southern hemisphere [12, 131 
13]. 132 
 133 
In our study, we used longitudinal data to: (1) determine the use of PIMs according to frailty status using 134 
the 2019 Beers Criteria; (2) identify medications used by frail and non-frail women that should be 135 
flagged as potentially inappropriate and harmful depending on individual health factors; and (3) 136 
determine the association between frailty and PIMs, adjusted for other characteristics associated with 137 




Study population and linked data source 142 
 143 
We included participants from the 1921 to 1926 cohort enrolled in the Australian Longitudinal Study on 144 
Women’s Health (ALSWH); details about the cohort are provided elsewhere [14]. Participants were 145 
initially invited to complete three-yearly surveys from 1996 to 2011, and thereafter six-monthly surveys; 146 
the ALSWH is an on-going study. In our study, participants were followed over time from 2003 to 2017. 147 
Data of ALSWH participants were linked to data from the Pharmaceutical Benefits Scheme (PBS), 148 
Australia’s government program for subsidised medications and health services for eligible citizens and 149 
permanent residents who have a Medicare card. The PBS has been widely used in medication 150 
utilisation studies and research purposes due to its informational benefits over self-reported data on 151 
medication use [15]. Participants were included in the study if they met the following criteria: 152 
 153 
a) Alive at 1 January 2003, and  154 
b) Had at least one medication record in the PBS in 2003, and  155 
c) Had PBS records with complete Anatomic Therapeutic Chemical (ATC) codes (7 digits), and  156 
d) Had self-reported frailty data in 2003, and 157 
e) Did not withdraw consent to linking data to the PBS prior to 2017. 158 
 159 
A stepwise flowchart of the inclusion process is included as a supplementary file (Online Resource 1).  160 
 161 
Potentially inappropriate medication use  162 
 163 
Participants were classified as PIM users if they used at least one PIM at each year. PIMs were 164 
examined using the 2019 Beers Criteria [3] using medication information from the PBS according to the 165 
ATC classification [16]. PIMs were identified based on the table ‘2019 American Geriatrics Society 166 
Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults’, which included PIMs to 167 
avoid regardless of underlying diseases [3]. Although some PIMs were classified only as medication 168 
classes and not as individual medications in the table, we counted and presented PIMs as unique 169 
medications; all medications and medication classes from the table were included in the PIM count 170 
regardless of recommendations that may have included avoidance criteria. There were two categories 171 
of PIMs used in this study; the first considered use of ≥3 PIMs, 1-2 PIMs, or no PIMs, which was 172 
presented descriptively. The second included participants who used ≥1 PIM, or no PIMs, to determine 173 
medications used by frail and non-frail participants that should be flagged as potentially inappropriate 174 
and harmful depending on individual health factors, as well as in the regression analyses that 175 
determined the association between frailty and use of PIMs.  176 
 177 
Frailty measure 178 
 179 
Frailty status of participants was identified using the FRAIL (Fatigue, Resistance, Ambulation, Illness, 180 
& Loss of Weight) scale, which has previously been used with ALSWH participants and has been 181 
validated in the same cohort [17]. The FRAIL scale was developed by the Geriatric Advisory Panel of 182 
the International Academy of Nutrition, Health and Aging task force on frailty assessment among older 183 
adults [17]. The FRAIL scale categorises participants as frail or non-frail based on deficits in five 184 
domains, i.e. ambulation (ability to walk at least 100m), resistance (ability to climb a flight of stairs), 185 
fatigue, presence of >5 pre-specified illnesses, and weight loss of ≥5% between consecutive surveys. 186 
Participants were scored positive if they had any deficit, and ranged from 0 for non-frail, to 5 for most 187 
frail; participants were considered frail if they scored >2 [17].  188 
 189 
Explanatory variables 190 
 191 
Explanatory variables included socio-demographic data (age at baseline, education level categorised 192 
as below Year 12, or Year 12 and above, and whether participants lived alone). Other variables included 193 
time (in years), whether participants had a Department of Veterans Affairs’ coverage, number of general 194 
practitioner (GP) visits in the last 12 months categorised as ≤4 or >4, whether they had a hospital 195 
admission in the last 12 months, number of chronic diseases categorised as <4 and ≥4, if they had a 196 
fall in the last 12 months, and if they had continuous polypharmacy. If missing, data were carried forward 197 
where necessary. Continuous polypharmacy was defined as the same unique medication that was used 198 
in two periods at each year, 1 April to 30 June, and 1 October to 31 December, to capture medications 199 
taken on a regular basis; these months were selected to avoid underestimating medication use because 200 
stockpiling of medications has been reported to occur towards the end of each year in Australia [18]. 201 
Chronic diseases were deemed to be enduring if reported at any survey, and included hypertension, 202 
heart disease (myocardial infarction, angina or other heart problems), diabetes mellitus, stroke, 203 
respiratory disease (bronchitis, asthma or emphysema), cancer, mental illness (Alzheimer’s 204 
disease/dementia, depression or anxiety/nervous disorder), arthritis (osteoarthritis and rheumatoid 205 
arthritis) and osteoporosis.  206 
 207 
Statistical analyses 208 
 209 
Stata® IC version 16 was used to perform all analyses [19]. Descriptive statistics were used to determine 210 
the proportion of participants using PIMs (≥3 PIMs, 1-2 PIMs, and no PIMs) for frail and non-frail 211 
participants, and to identify PIMs (≥1 PIM and no PIMs) used by both groups, from 2003 (age 77 to 82 212 
years) to 2017 (age 91 to 96 years). Generalised estimating equations (GEEs) using log-binomial 213 
regressions with robust standard errors and an unstructured correlation matrix were used to determine 214 
the association between frailty and PIMs using longitudinal data. First, multicollinearity between 215 
variables was identified based on Pearson correlation coefficients greater than 0.8, and confirmed with 216 
variance inflation factor values greater than 10 [20]; collinear variables were removed. Preliminary 217 
univariate regressions were then conducted, and variables significant at the 0.25 level were included in 218 
the first multivariable model [21]. A backward stepwise elimination method was used to obtain the final 219 
model, starting from removal of the least significant variable at the 0.05 level. Effect estimates are 220 
presented as risk ratios (RR) with confidence intervals of 95% (95% CI).  221 
 222 
Ethics approval 223 
 224 
The ALSWH has ongoing ethical approval from the University of Queensland (UQ) (reference 225 
2004000224) and the University of Newcastle (UoN) (reference H-076-0795) Human Research Ethics 226 
Committees (HREC), and also for the health record linkage (UQ: reference 2012000132 and UoN: 227 
reference H-2011-0371). Our study was approved by the ALSWH Data Access Committee. Access to 228 
national data collections was approved by the Australian Institute of Health and Welfare HREC 229 




This study included 9355 participants aged 77 to 82 years in 2003. Participant characteristics at 234 
baseline (2003) are presented as a supplementary file (Online Resource 2). An additional 974 235 
participants did not have frailty data and were excluded from analysis, but their characteristics were 236 
similar to those participants analysed. Compared to frail participants, non-frail participants had a lower 237 
median number of medications in 2003 (median=10, IQR: 7-15), which increased over time to 2017 238 
(median=12, IQR: 8-15). These findings are detailed in Online Resource 3. The high prevalence of PIMs 239 
(≥1) among older women remained constant, as they aged from 77 to 82 years (76.2%) to 91 to 96 240 
years (78.3%). The prevalence of frailty was fairly low and increased slightly as they aged, i.e. 22.8% 241 
to 29.5%. At baseline, PIM users accounted for the majority of frail (84.7%) and non-frail (73.6%) 242 
participants.  243 
 244 
Fig.1 summarises the proportion of frail participants using PIMs overlayed by the median number of 245 
medications used each year; 84.8% of frail participants used ≥1 PIM at baseline. When participants 246 
were 77 to 82 years at 2003, the majority were using ≥3 PIMs (74.2%), followed by non-PIM users 247 
(15.3%), and users of 1-2 PIMs (10.6%); there were no discernible changes in proportion over time to 248 
2017 when participants were aged 91 to 96 years. The median number of medications remained 249 
relatively constant: 14 in 2003 (interquartile range, IQR: 10-19), and 13 in 2017 (IQR: 10-17). Fig. 2 250 
illustrates the proportion of non-frail participants using PIMs, with 73.7% who used ≥1 PIM at baseline. 251 
In comparison to those who were frail, there was a lower proportion of non-frail participants using ≥3 252 
PIMs in 2003 (58.5%); the proportion of non-frail non-PIM users (26.4%) and non-frail users of 1-2 PIMs 253 
(15.2%) was higher. At 2017, the proportion of participants using ≥1 PIM remained fairly constant 254 
(76.7%) in comparison to 2003. However, there was an increase in the proportion of non-frail 255 
participants using ≥3 PIMs (66.0%) and a decrease in non-frail participants using 1-2 PIMs (10.7%). 256 
This information is summarised in Online Resource 4.  257 
 258 
Fig. 3 and Fig. 4 depict medications used by frail and non-frail participants, respectively, that should be 259 
flagged as potentially inappropriate and harmful depending on individual health factors. These 260 
medications were included in the graphs provided they appeared in the top five at any year from 2003 261 
to 2017. This resulted in a total of 12 medications for frail participants in 2003 which included: aspirin 262 
(31.3%; ATC codes: B01AC06, B01AC30), temazepam (24.7%; ATC code: N05CD07), omeprazole 263 
(24.5%; ATC code: A02BC01), digoxin (15.9%; ATC code: C01AA05), pantoprazole (11.0%; ATC code: 264 
A02BC02), esomeprazole (10.6%; ATC code: A02BC05), oxazepam (10.1%; ATC code: N05BA04), 265 
metoclopramide (9.1%; ATC code: A03FA01), diazepam (8.6%; ATC code: N05BA01), meloxicam 266 
(7.7%; ATC code: M01AC06), amitriptyline (6.4%; ATC code: N06AA09) and rabeprazole (5.0%; ATC 267 
code: A02BC04). In 2017, there was reduced use of aspirin (13.4%) and omeprazole (8.2%), and 268 
increased use of pantoprazole (27.6%), esomeprazole (27.4%) and metoclopramide (17.5%), 269 
compared to 2003. When compared to frail participants, two additional medications (diclofenac; ATC 270 
codes: M01AB05, D11AX18, M01AB55 and risperidone; ATC code: N05AX08) appeared in the top five 271 
for non-frail participants from 2003 to 2017. Despite a low prevalence in 2003 for diclofenac (6.9%) and 272 
risperidone (0.5%), the use of diclofenac decreased over time (to 1.1%) while that of risperidone 273 
increased over time (7.8%). There were no other discernible changes for the same medications from 274 
the frail group. This information is presented in the supplementary file (Online Resource 5).  275 
 276 
In terms of the regression analyses, none of the explanatory variables were collinear. Univariate log-277 
binomial regressions using GEEs indicated that there was no evidence for living alone and the use of 278 
PIMs (p=0.356), thus this variable was not included in subsequent models. Table 1 presents the 279 
variables that were included in the final model. Frailty was associated with a 2% increase in risk of using 280 
PIMs (RR 1.02; 95% CI: 1.01, 1.03). Participants with ≥4 chronic diseases had a 6% higher risk of using 281 
PIMs (RR 1.06; 95% CI: 1.05, 1.07) compared to those with <4 chronic diseases. Participants with 282 
continuous polypharmacy had a 7% higher risk of using PIMs (RR 1.07; 95% CI: 1.06, 1.07). Hospital 283 
admissions and >4 GP visits in the last 12 months, and having DVA coverage were also associated 284 
with higher risk of using PIMs, while an education level of Year 12 and above was associated with a 285 
3% lower risk of using PIMs (RR 0.97, 95% CI 0.95, 0.98). Age at baseline and time (in years) did not 286 
significantly contribute to the model.  287 
 288 
Discussion  289 
 290 
Almost 80% of women in our study used medications that could have been potentially inappropriate as 291 
according to the Beers Criteria 2019, and approximately one-third of these women were frail. Frail 292 
women had a 2% increased risk of using PIMs, when adjusted for other characteristics. Commonly used 293 
medications/medication classes that may have been potentially inappropriate among frail and non-frail 294 
women included benzodiazepines, proton-pump inhibitors, nonsteroidal anti-inflammatory drugs, 295 
aspirin and digoxin, and risperidone was an additional contributor among non-frail women. 296 
 297 
When PIM use was determined in the context of frailty, use of one or more PIMs among frail (80%) and 298 
non-frail (75%) women remained constant as they aged from 77 to 82 years (in 2003) to 91 to 96 years 299 
(in 2017). Among non-frail PIM users, the proportion of women using three or more PIMs increased 300 
over time, while there was a decrease in the proportion of women who used one to two PIMs; this 301 
indicates a transition between these two groups of non-frail PIM users which occurred predominantly in 302 
their 80’s. The higher number of women using more PIMs may reflect prescribing practices that are 303 
disease-specific and guideline-driven, increasing the risk of using PIMs. The use of PIMs estimated in 304 
our study approximated previous studies that used the Beers Criteria and reported prevalence of PIMs 305 
that ranged from 50% to 70% for frail women [22, 23]. However, prevalence in our study appeared 306 
higher than that reported by Maclagan et al. (2017), with 48% in the frail group, 39% in the non-frail 307 
group, and 43% in the pre-frail group [8]. Reasons for the variation in the prevalence of PIMs according 308 
to frailty is common across many studies; it could be due to the use of different tools to determine PIMs 309 
and frailty, and various study settings such as nursing homes or own homes, the availability of 310 
medications across countries, prescribing habits, fear of discontinuing medications, and ideological and 311 
market pressures [9].  312 
 313 
Frailty was associated with a 2% increased risk of using PIMs (RR 1.02; 95% CI: 1.01, 1.03) and 314 
although small it is nonetheless an important factor. Frailty is known to increase the risk of 315 
polypharmacy, which in turn increases the risk of using PIMs [24]. Polypharmacy is also a strong 316 
predictor of PIMs [25] thus increasing the association between frailty and PIMs. In our study, median 317 
medication use among frail women was higher than among non-frail women. Our study found that 318 
despite adjustment for other characteristics, continuous polypharmacy (medications taken on a regular 319 
basis) increased the risk of using PIMs by 7%. Although not a novel finding, this provides evidence that 320 
despite interventions, polypharmacy is still contributing to the use of PIMs among frail older adults.  321 
 322 
The Asia-Pacific Clinical Practice Guidelines for the Management of Frailty recommend a careful 323 
approach to polypharmacy in order to reduce the prevalence of PIMs [26], indicating that frailty could 324 
be an important indicator of health outcomes. In the context of frailty, increase risk of using medications 325 
that may be potentially inappropriate in the context of frailty is clinically important for a few reasons. 326 
Pharmacokinetic and pharmacodynamic characteristics of older adults exacerbate adverse events in 327 
the presence of frailty [9, 27], further adding to the complexities and adverse events associated with the 328 
use of PIMs [1, 2]. Frail older adults suffer deterioration in balance, leading to walking impairment and 329 
increasing the risk of falls, which could be aggravated in those using PIMs that affect gait and balance. 330 
Falls is a major geriatric symptom among older adults and has been reported as the second leading 331 
cause of death globally, with over one-third of community-dwelling older adults falling annually [28].  332 
 333 
In considering other characteristics associated with the use of PIMs, the findings of our study are 334 
generally consistent with literature. We observed that age at baseline and an increase in age only had 335 
a small effect on the risk of PIMs, which is similar to the findings by Miller et al. (2017) [29]; similar to 336 
our study, Miller et al. also reported that lower education level was associated with a lower risk of using 337 
PIMs. It is possible that literacy could improve the awareness and knowledge of disease symptoms, 338 
thus increasing the number of GP consultations and medications which make people more vulnerable 339 
to using PIMs [9, 29]. Having a DVA coverage increased the risk of polypharmacy and this could be 340 
due to a higher level of medical attention that DVA clients receive in comparison to other patients; 341 
veterans receive 1.5 additional consultations a year in comparison to their community counterparts, 342 
whereas war widows receive 2.5 additional consultations a year [30]. Multimorbidity exhibited a strong 343 
association with use of PIMs, which is expected given that multimorbidity increases the risk of 344 
polypharmacy. The presence of four or more chronic diseases increased the risk of using PIMs by 6% 345 
in our study, similar to the findings by Bolina et al. (2019) [9]; as early as 2001 Fried et al. reported an 346 
association between frailty and multimorbidity among women [7]. Hospital admissions in the past year 347 
were also associated with a higher risk of using PIMs, consistent with the study by Bolina et al. [9]. 348 
Recently, a Canadian study by Weir et al. (2020) found that upon hospital discharge, two-thirds of older 349 
adults hospitalised for medical or surgical purposes were prescribed with at least one PIM upon 350 
discharge [31]. Finally, more than four GP visits in the past year was also associated with an increase 351 
in risk of using PIMs (5%) and may indicate the potential role that GPs can play in optimising 352 
medications for older adults.  353 
 354 
Both frail and non-frail women used medications listed in the Beers Criteria 2019 that have frequently 355 
been reported in other studies [8, 10, 11], i.e. benzodiazepines, drugs for gastrointestinal disorders 356 
such as proton-pump inhibitors (PPIs) and metoclopramide, and nonsteroidal anti-inflammatory drugs 357 
(NSAIDs). Benzodiazepines should be avoided among older people according to the Beers Criteria, 358 
although benzodiazepine anxiolytics (e.g. oxazepam and diazepam) and benzodiazepine hypnotics 359 
(e.g. temazepam) were commonly used by women in our study. The incidence of benzodiazepine side 360 
effects, predominantly those of the central nervous system (CNS) such as fatigue, drowsiness, ataxia 361 
and confusion, increase with age in older adults [3]. Symptoms worsen in long-acting benzodiazepines, 362 
such as diazepam, and are dose-related. Amitriptyline was also commonly used in our study. Reports 363 
of an association between antipsychotics and tricyclic antidepressants, and an increased risk of hip 364 
fractures, are due to its anticholinergic properties, which increase in relation to dose [32]. However, the 365 
high use of these medications indicates a clinical need among women in our study. While symptomatic 366 
treatment with tricyclics may be considered provided non-pharmacological alternatives have been 367 
exhausted, it is important to consider a ‘drug holiday’, titrating doses starting from the lowest, and limited 368 
duration of use [32]. 369 
 370 
It was interesting to note that omeprazole, esomeprazole, pantoprazole and rabeprazole were 371 
chronically used by women in our study. High use of PPIs may be due to the frequent use of meloxicam 372 
and diclofenac which was evident. PPIs were reported as one of the most commonly used PIMs in other 373 
studies using the Beers Criteria [33] and the Screening Tool of Older Person’s potentially inappropriate 374 
Prescriptions (STOPP) criteria [34]. Although PPIs are well tolerated short-term, prolonged use may 375 
result in Clostridium difficile-associated diarrhoea, bone loss and fractures [3], increasing the risk of 376 
falls. It has been reported that patients are often advised to continue using PPIs indefinitely upon 377 
hospital discharge [33], and therefore it is important that the clinical need for PPIs be reviewed.  378 
 379 
Risperidone was an additional PIM in the non-frail group. Higher plasma concentrations of risperidone 380 
are the result of its poor penetration of the blood brain barrier resulting in hyperprolactinemia and 381 
antipsychotic-induced osteoporosis [35]. Recent literature has presented compelling evidence that 382 
antipsychotic treatment results in decreases of bone mineral density which can be a characterisation of 383 
frailty [36]. Hyperprolactinemia occurs because antipsychotics block D2 dopamine receptors of the 384 
lactotrophs in the anterior pituitary [35] and may explain why risperidone was not used among frail 385 
women, as opposed to non-frail women. Nevertheless, caution should be taken when prescribing 386 
risperidone for any age but especially for long-term use in older people. 387 
 388 
Clinical implications  389 
 390 
Our study has several clinical implications. Acknowledging and understanding the characteristics 391 
associated with the use of PIMs in our study allows for improved assessment of healthcare amongst 392 
oldest old women [11]. Our findings that indicate almost one-third of women had frailty, highlights the 393 
importance of recognising frailty as an indicator of health outcomes, especially in the context of 394 
medication use. The decision-making process regarding medication use should be based on the 395 
individual’s underlying comorbidities, functional status and treatment goals [8]. Frailty forms the basis 396 
of geriatric medicine, and geriatricians globally have advocated for the screening of frailty during health 397 
care access for older adults [37]. It is important to consider deprescribing for frail older adults, 398 
particularly those aged 75 years and over, and it is important to consider benefits versus risk. Medication 399 
optimisation is a pillar of patient-centred care and algorithms have been developed to identify PIMs [38] 400 
exclusively for frail older adults [39]. Patients’ preferences and considerations should be taken into 401 
account, given the dynamic nature of frailty and the adverse events associated with PIMs that may vary 402 
between individuals.  403 
 404 
The Beers Criteria identifies medications that are potentially inappropriate and that should generally be 405 
avoided, thus there is a need to emphasise that use of PIMs may be justified in some circumstances. It 406 
is neither intended to supplant clinical decisions and to be used punitively, nor override individual 407 
preferences and needs [3]. The use of the Beers Criteria to identify PIMs in our longitudinal study 408 
indicate that older women, particularly those aged 77 years and above, are prescribed medications that 409 
may be potentially inappropriate. For instance, aspirin is to be avoided at doses of more than 410 
325mg/day, digoxin is to be avoided as first-line therapy as a rate control agent in atrial fibrillation and 411 
in heart failure, NSAIDs are to be avoided as chronic use except where other alternatives are not 412 
effective and the person is taking a gastro protective agent, and PPIs should not be used for more than 413 
eight weeks, unless indicated [3]. This highlights the importance of regularly reviewing medications for 414 
older people, and medication reviews should be aimed at ascertaining the appropriateness of 415 
medications listed as PIMs, particularly those identified in our study. The review process should be 416 
complemented by implicit interventions such as using a treatment algorithm to guide the decision-417 
making process.  418 
 419 
Finally, the majority of women in our study were community-dwelling, and this is comparable to the 420 
Australian Bureau of Statistics’ Census of Population and Housing [40]. Most recent data in the 421 
Australian Bureau of Statistics (2016) indicate that 58% of older people resided in the community, while 422 
our study depicted that 58.26% of women were community-dwelling in the same year. It is known that 423 
older people prefer living in their homes rather than moving into frail care, a phenomenon that is 424 
encouraged by the Australian government [41]. Our finding is important because it draws attention to 425 
frailty among community-dwelling older people, and the increased awareness may stimulate 426 
development of additional home-care services specifically targeted for frail people, including an 427 
increase in regular medication reviews.  428 
 429 
Strengths and limitations  430 
 431 
There were limitations in our study. The majority of women in our study were community-dwelling and 432 
our findings may not be generalizable to older adults across Australia who may be living in aged care 433 
facilities. The lack of outcomes, such as increased risk of morbidity and mortality due to the association 434 
between frailty and PIMs, needs to be acknowledged; the clinical data required for such evaluations 435 
was not available in this study dataset. The PBS dataset does not include medications dispensed on 436 
non-subsidised ‘private’ prescriptions, or medications that can be purchased without a prescription, 437 
therefore we may have underestimated use of PIMs. Although the ALSWH surveys may introduce recall 438 
bias due to its self-report nature, insights obtained from this large longitudinal study may take 439 




This study provides new insight regarding the use of PIMs among frail older women aged 77 to 96 444 
years, and the characteristics associated with the use of PIMs. Overall, two-thirds of women in this 445 
study commonly used medications that may be potentially inappropriate, and approximately 80% of frail 446 
women used at least one PIM. Commonly used medications that may have been potentially 447 
inappropriate among frail and non-frail women were benzodiazepines, PPIs and NSAIDs, with 448 
risperidone as an additional contributor among non-frail women. Frailty was associated with a 2% 449 
increased risk of using PIMs. Characteristics such as continuous polypharmacy, four or more chronic 450 
diseases, having a DVA coverage, past hospital admissions and four or more GP visits in the past year 451 
increased the risk of using PIMs. Our study supports the need to consider these characteristics, and 452 
we recommend regular medication reviews to optimise medications for frail older women, particularly 453 
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Fig. 1 Proportion of frail participants aged 77 to 96 years using potentially inappropriate medications overlayed by median number of medications from 2003 
to 2017 
 



















Fig. 2 Proportion of non-frail participants aged 77 to 96 years using potentially inappropriate medications overlayed by median number of medications from 
2003 to 2017 
 








































Fig. 4 Top five potentially inappropriate medications among non-frail participants aged 77 to 96 years from 2003 to 2017 
 
 
Table 1 Adjusted and unadjusted results for the associations between frailty and potentially inappropriate medications (PIMs) from 2003 to 2017 using 
generalised estimating equations (GEEs) for log-binomial regressions 
 
 Unadjusted models for women 
with PIMs a 
Adjusted model for women with 
PIMS 
Risk ratio (95% CI b) p-value Risk ratio (95% CI) p-value 
Frailty status  
   Non-frail Reference Reference 
   Frail 1.05 (1.04, 1.06) <0.001 1.02 (1.01, 1.03) <0.001 
Time (in years) 1.01 (1.00, 1.01) <0.001 1.00 (1.00, 1.00) <0.001 
Age at baseline 1.00 (0.99, 1.01) 0.077 1.00 (1.00, 1.01) 0.014 
Education level 
   Below Year 12 Reference Reference 
   Year 12 and above 0.94 (0.93, 0.96) <0.001 0.97 (0.95, 0.98) <0.001 
DVA c Status 
   No Reference Reference 
   Yes 1.05 (1.04, 1.06) <0.001 1.02 (1.01, 1.03) 0.004 
Number of GP d visits in the last 12 months 
   ≤4 visits Reference Reference 
   >4 visits 1.08 (1.07, 1.09) <0.001 1.05 (1.04, 1.06) <0.001 
Hospital admissions in the last 12 months 
   No Reference Reference 
   Yes 1.05 (1.04, 1.06) <0.001 1.02 (1.01, 1.02) <0.001 
Number of chronic diseases  
   <4 Reference Reference 
   ≥4 1.11 (1.10, 1.12) <0.001 1.06 (1.05, 1.07) <0.001 
Falls in the last 12 months  
   No Reference Reference 
   Yes 1.01 (1.00, 1.02) 0.042 0.99 (0.98, 1.00) 0.062 
Presence of polypharmacy e 
   No Reference Reference 
   Yes 1.09 (1.09, 1.10) <0.001 1.07 (1.06, 1.07) <0.001 
 
a Potentially inappropriate medications 
b Confidence interval 
c Department of Veterans Affairs 
d General practitioner 
e Polypharmacy defined as continuous polypharmacy, i.e. the use of 5 or more medications, where each medication is counted as one if it appears in two time windows at each 
year (1 Apr-30 Jun) & (1 Oct-31 Dec) 
 
Note: The reference class was ‘no PIMS’  
 
